Welcome to Markets Desk, your midday read on what's moving and why.
Oracle is taking a beating in today's session after announcing plans to raise forty billion dollars through a combination of debt and equity issuance. That kind of capital raise signals aggressive expansion ambitions, likely tied to AI infrastructure buildout, but it's dilutive by nature, and markets are repricing the stock accordingly. Whether that's an entry point depends entirely on your conviction in Oracle's cloud trajectory.
Shifting to biotech, Genmab is drawing attention after presenting encouraging clinical data for epcoritamab in elderly patients with diffuse large B-cell lymphoma who can't tolerate standard chemotherapy. For a population with historically limited options, positive efficacy signals here matter, and the market is watching closely to see how this shapes Genmab's commercial pipeline going forward.
Meanwhile in consumer staples, JBS USA confirmed it will shutter two processing facilities, one in Pennsylvania and one in Tennessee. The closures are framed as operational streamlining, but they reflect continued margin pressure in the protein sector as input costs remain elevated. Employees are promised transition support, though the broader labor impact in those communities will be felt regardless.
That's the tape. Markets Desk, signing off the floor.
